Clinical Global Impression-Severity

Biomarker

Also known as: Clinical Global Impressions-Severity

Related News

Compass Pathways Reports Positive Phase 3 Results for COMP360 in Treatment-Resistant Depression

Mar 09, 2026

Compass Pathways announced positive Phase 3 data for COMP360 psilocybin therapy in treatment-resistant depression, showing statistically significant improvements in depression scores and durability through 26 weeks, with plans to file for FDA approval in Q4 2026.

COMPASS Pathways Reports Positive Phase 3 Results for Psilocybin in Treatment-Resistant Depression

Mar 09, 2026

COMPASS Pathways announced positive Phase 3 results for COMP360 psilocybin in treatment-resistant depression, showing statistically significant improvements across two pivotal trials with durability signals through 26 weeks and a generally well-tolerated safety profile.